» Articles » PMID: 28246295

Autophagy Inhibits the Accumulation of Advanced Glycation End Products by Promoting Lysosomal Biogenesis and Function in the Kidney Proximal Tubules

Overview
Journal Diabetes
Specialty Endocrinology
Date 2017 Mar 2
PMID 28246295
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Advanced glycation end products (AGEs) are involved in the progression of diabetic nephropathy. AGEs filtered by glomeruli or delivered from the circulation are endocytosed and degraded in the lysosomes of kidney proximal tubular epithelial cells (PTECs). Autophagy is a highly conserved degradation system that regulates intracellular homeostasis by engulfing cytoplasmic components. We have recently demonstrated that autophagic degradation of damaged lysosomes is indispensable for cellular homeostasis in some settings. In this study, we tested the hypothesis that autophagy could contribute to the degradation of AGEs in the diabetic kidney by modulating lysosomal biogenesis. Both a high-glucose and exogenous AGE overload gradually blunted autophagic flux in the cultured PTECs. AGE overload upregulated lysosomal biogenesis and function in vitro, which was inhibited in autophagy-deficient PTECs because of the impaired nuclear translocation of transcription factor EB. Consistently, streptozotocin-treated, PTEC-specific, autophagy-deficient mice failed to upregulate lysosomal biogenesis and exhibited the accumulation of AGEs in the glomeruli and renal vasculature as well as in the PTECs, along with worsened inflammation and fibrosis. These results indicate that autophagy contributes to the degradation of AGEs by the upregulation of lysosomal biogenesis and function in diabetic nephropathy. Strategies aimed at promoting lysosomal function hold promise for treating diabetic nephropathy.

Citing Articles

Advanced Glycation End-Product-Modified Heat Shock Protein 90 May Be Associated with Urinary Stones.

Takata T, Inoue S, Kunii K, Masauji T, Moriya J, Motoo Y Diseases. 2025; 13(1).

PMID: 39851471 PMC: 11764404. DOI: 10.3390/diseases13010007.


AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications.

Wang B, Jiang T, Qi Y, Luo S, Xia Y, Lang B Cardiovasc Drugs Ther. 2024; .

PMID: 39499399 DOI: 10.1007/s10557-024-07639-0.


Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules.

Matsui S, Yamamoto T, Takabatake Y, Takahashi A, Namba-Hamano T, Matsuda J Autophagy. 2024; 21(3):583-597.

PMID: 39385699 PMC: 11849939. DOI: 10.1080/15548627.2024.2410621.


Pathological mechanisms of kidney disease in ageing.

Yamamoto T, Isaka Y Nat Rev Nephrol. 2024; 20(9):603-615.

PMID: 39025993 DOI: 10.1038/s41581-024-00868-4.


MondoA and AKI and AKI-to-CKD Transition.

Maeda S, Sakai S, Takabatake Y, Yamamoto T, Minami S, Nakamura J J Am Soc Nephrol. 2024; .

PMID: 38819935 PMC: 11387036. DOI: 10.1681/ASN.0000000000000414.